We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.64 | -1.01% | 161.00 | 163.6923 | 161.14 | 162.73 | 5,178,876 | 00:39:44 |
From May 2021 to May 2024
By Stephen Nakrosis
AbbVie Inc. on Tuesday said the U.S. Food and Drug Administration approved Qulipta for the preventive treatment of episodic migraine in adults.
The company said Qulipta, or atogepant, "demonstrated statistically significant, clinically meaningful rapid and continuous reductions in mean monthly migraine days among adults with episodic migraine compared to placebo."
Michael Severino, vice chairman and president of AbbVie, said "Millions of people living with migraine often lose days of productivity each month because attacks can be debilitating. Qulipta can help by reducing monthly migraine days with a once-daily, oral dose that works quickly and continuously."
AbbVie said it is the only pharmaceutical company offering three treatments across the full spectrum of migraine.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 28, 2021 19:15 ET (23:15 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
